Organization | X-act Cologne Clinical Research GmbH

X-act Cologne Clinical Research GmbH Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Cologne Germany (1994)

Organization Overview

First Clinical Trial

2013

NCT01621256

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2018

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

X-act Cologne Research GmbH

Active Ingredients

Drugs in Phase 3 Trials (11)

Key: X-act Cologne Clinical Research GmbH (0) Acquired (11)

autologous mononuclear stem cell (1 trial)

bendamustine (treanda) (1 trial)

epirubicin (ellence) (2 trials)

etoposide (vepesid) (1 trial)

fludarabine (fludara) (1 trial)

ifosfamide (ifex) (1 trial)

melphalan (alkeran) (1 trial)

peripheral blood hematopoietic cell (1 trial)

sargramostim (leukine) (2 trials)

stem cells (1 trial)

urea (1 trial)

Drugs in Phase 2 Trials (18)

Key: X-act Cologne Clinical Research GmbH (3) Acquired (15)

alemtuzumab (campath) (1 trial)

capecitabine (xeloda) (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (3 trials)

clobetasol (dermovate) (1 trial)

dexamethasone (1 trial)

doxorubicin (Doxil) (1 trial)

eltrombopag (promacta) (1 trial)

gemcitabine (gemzar) (2 trials)

Isatuximab (Sarclisa) (1 trial)

lenalidomide (revlimid) (1 trial)

paclitaxel (taxol) (1 trial)

panitumumab (vectibix) (5 trials)

pemetrexed (alimta) (1 trial)

ponatinib (iclusig) (1 trial)

sodium chloride (1 trial)

trastuzumab (herceptin) (1 trial)

viprinex (1 trial)

Drugs in Phase 1 Trials (1)

Key: X-act Cologne Clinical Research GmbH (0) Acquired (1)

mitomycin c-induced peripheral blood mononuclear cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Deafness (Phase 2)

Ear Diseases (Phase 2)

Hearing Disorders (Phase 2)

Hearing Loss (Phase 2)

Hearing Loss, Sensorineural (Phase 2)

Lichen Planus (Phase 2)

Lichen Planus, Oral (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 16
# of Trial APIs: 30